血栓通联合依达拉奉治疗急性脑梗死的效果及安全性研究

Efficacy and safety of Xuetong combined with edaravone in the treatment o f acute cerebral infarction

目的:探讨并研究用血栓通联合依达拉奉治疗急性脑梗死(acute cerebral infarct,ACI)的临床效果及安全性。方法:将近年来德州市平原县第一人民医院收治的100例ACI患者按照随机序贯综合平衡法分为血栓通联合依达拉奉组(TTE组,n=50)与血栓通组(TT组,n=50)。对两组患者均进行常规治疗,在此基础上用血栓通联合依达拉奉对TTE组患者进行治疗,用血栓通对TT组患者进行治疗,然后比较两组患者病情的改善情况及其不良反应的发生率。结果:治疗后,TTE组患者病情的总改善率高于TT组患者,P<0.05。用药后,两组患者不良反应的发生率相比,P>0.05。结论:用血栓通联合依达拉奉治疗ACI可显著改善患者的病情,提高其临床疗效,且用药的安全性较高。

objective:to study and research with thrombosis through joint with dara in treatment of acute cerebral infarction(acute cerebral infarct,ACI)of clinical efficacy,and safety.Methods:In recent years,100 ACI patients admitted to The First People’s Hospital of Pingyuan County,Dezhou City were divided into thrombonedaravone group(TTE group,n=50)and Thrombon-Tt group(n=50)according to random sequential comprehensive balance method.Patients in both groups were given routine treatment.On this basis,patients in TTE group were treated with thrombantone combined with edaravone,and patients in TT group were treated with thrombantone.Then,the improvement of the condition of patients in the two groups and the incidence of adverse reactions were compared.Results:After treatment,the total improvement rate of TTE group was higher than TT group(P<0.05).After treatment,the incidence of adverse reactions between the two groups was P>0.05.Conclusion:Thrombocyto combined with edaravone in the treatment of ACI can significantly improve the patient’s condition,improve its clinical efficacy,and the safety of drug.